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Abstract
Geoffrey Wingfield Harris’ demonstration of hypothalamic hormones regulating pituitary function
led to their structural identification and therapeutic utilization in a wide spectrum of diseases.
Amongst these, Gonadotropin Releasing Hormone (GnRH) and its analogs are widely employed in
modulating gonadotropin and sex steroid secretion to treat infertility, precocious puberty and many
hormone-dependent diseases including endometriosis, uterine fibroids and prostatic cancer. While
these effects are all mediated via modulation of the pituitary gonadotrope GnRH receptor and the
Gq signaling pathway, it has become increasingly apparent that GnRH regulates many extrapituitary
cells in the nervous system and periphery. This review focuses on two such examples, namely GnRH
analog effects on reproductive behaviors and GnRH analog effects on the inhibition of cancer cell
growth. For both effects the relative activities of a range of GnRH analogs is distinctly different from
their effects on the pituitary gonadotrope and different signaling pathways are utilized. As there is
only a single functional GnRH receptor type in man we have proposed that the GnRH receptor can
assume different conformations which have different selectivity for GnRH analogs and intracellular
signaling proteins complexes. This ligand-induced selective-signaling recruits certain pathways
while by-passing others and has implications in developing more selective GnRH analogs for highly
specific therapeutic intervention.
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1. Introduction
This article arises from the Geoffrey Wingfield Harris Memorial Lecture delivered at the
International Neuroendocrinology Congress held in Pittsburgh in 2006 entitled “GnRH: A
Peptide for all Seasons”. It is dedicated to three neuroendocrinology colleagues who recently
passed away. Sam Yen died on 26 December 2006 after a life-time of major research
contributions to gynecological endocrinology including many of the earliest studies on GnRH
effects in women. Sam (Don) McCann pioneered the quest to discover the hypothalamic factor
regulating gonadotropins and Richard (Dick) Peter who elucidated the neuroendocrine control
of gonadotropins in fish. Both died early this year.
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Following the pioneering discoveries of the magnocellular neurosecretory neurons by Ernst
and Berta Schaller, Geoffrey Harris (Fig. 1) conducted a series of seminal studies in the 1940s
that demonstrated that a capillary portal vessel system which connected the hypothalamic
region of the central nervous system with the pituitary (see review [46]). He demonstrated this
by means of a series of exquisite experiments including the injection of India ink into the
capillary network (Fig. 2). He went on to propose that this portal system conducted humoral
factors from the brain to the pituitary to regulate hormone secretion. In support of this
hypothesis, Harris further demonstrated that disruption of these portal vessels gave rise to a
decline in reproductive activity in ferrets exposed to stimulatory photoperiods. There was
considerable opposition to Harris’ conclusions by Solly Zuckerman’s group doing similar
experiments and it is testimony to Harris’ experimental prowess and his tenacity that his
proposal endured and the concept of hypothalamic hormone regulation of pituitary function
was spawned. The quest to determine the structure of these releasing factors was spearheaded
by the groups of McCann, Schally and Guillemin. In 1971, after a monumental purification
effort from millions of pig brains, Schallyfirst announced the structure of the decapeptide
GnRH [5,80,125] (Fig. 3). This discovery, together with that of the other hypothalamic
hormones, was a major breakthrough in neuroendocrinology and has culminated in the legacy
of extensive clinical applications of hypothalamic peptide analogs which impinge on almost
all fields of medicine. GnRH analogs, themselves, are extensively used as interventive
therapies in a wide spectrum of pathologies which is reffected in annual sales of about $2
billion. Chronic pharmacological administration of GnRH agonists induces gonadotrope
desensitization and an inhibition of gonadotropin secretion resulting in an inhibition of gonadal
sex steroid hormones and gametogenesis. This is a slow process requiring one to two weeks.
In contrast, GnRH antagonists have an immediate inhibition of gonadotropins; the rate of
decline equating that of their half life. Therapeutic applications in hormone-dependent diseases
include prostatic, breast and ovarian cancer, endometriosis, uterine fibroids, precocious
puberty, polycystic ovarian syndrome, and acute intermittent porphyria [7,16,24,25,33,37,92,
99]. Natural GnRH administered in hourly pulses (to mimic hypothalamic secretion) is
effective in treating hypogonadotropic hypogonadism (e.g. in anorexia nervosa and Kallman’s
syndrome) and in cryptorchidism. GnRH agonists and antagonists are also very extensively
used to inhibit endogenous gonadotropin to allow regulated add-back for the induction of
ovulation in vitro fertilization (IVF) treatment of infertility. GnRH antagonists also hold
promise as a new generation of male and female contraceptives with add-back gonadal steroids
[4,38,93,108].
While the primary function of GnRH is to regulate gonadotropins, it became apparent during
the ensuing 30 years since its discovery that the hormone and its receptors are also expressed,
and have actions, in many other tissues. These include various regions of the central and
peripheral nervous system, in most reproductive tissues, in many non-reproductive tissues, in
immune cells and also in many cancer cells [21,48].
Although the Geoffrey Harris lecture painted a broad canvas covering a wide spectrum of
GnRH research, some of these areas (such as intracellular signaling, GnRH receptors and
GnRH analogs) have been the subject of extensive and recent review [39,58,83,86,87,95,
104,105,126,135] and will not be reiterated in detail in this article. We would instead focus on
three extra-pituitary features of GnRH action. The first is the effects of GnRHs in stimulating
reproductive behaviors. The second relates to the direct inhibition of cancer cells by GnRHs
and analogs. For both of these the pharmacology of the effects of GnRH agonists and
antagonists is distinctly different from their effects on pituitary gonadotropin secretion. The
third arises from this phenomenon and encompasses the concept of ligand-induced selective-
signaling (LiSS) by GnRH analogs which we developed to explain the differing pharmacology
in different cellular environments [81,89,95]. In support of this we present evidence of the
existence of different conformations of the GnRH receptor which give rise to selective binding
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of GnRH analogs and differential intracellular signaling. In order to understand these
phenomena it is necessary to first briefly review the structures and molecular functioning of
GnRHs and GnRH receptors.
2. Diversity of GnRH structures
Following the structural elucidation of the mammalian GnRH, a number of studies on
hypothalamic extracts from various vertebrates claimed that their GnRHs were identical to the
mammalian structure. However, this conclusion was based on low-resolution gel filtration
separation of hypothalamic extracts and the use of antisera of poorly defined specificity. In
view of the structural diversity of the related oxytocin and vasopressin family of peptides we
considered that this conservation of GnRH structures was unlikely. Utilizing a range of
sequence-specific antisera against mammalian GnRH and ion exchange chromatography, we
demonstrated that a series of different structures of GnRH were present in different vertebrates
[64,65]. This set the scene for the isolation of the first novel GnRH from chicken hypothalamus
(chicken I GnRH) which differed by a single substitution of glutamine for arginine in position
8 (Fig. 3) [66,67]. Thirteen structural variants of GnRH have now been identified from all the
vertebrate classes, nine from protochordates and one from a species of octopus, see Refs. [2,
9,95,129]. These diverse structures represent “experiments of nature” over some 600 million
years and provide insight into conserved and functionally important residues. It is apparent
that the length of the peptide and the amino- and carboxyl-terminal domains are highly
conserved and that these features are important for receptor binding and activation.
Furthermore, the achiral amino acid, glycine, is conserved in position 6 in all the jawed
vertebrate GnRHs (Fig. 3) and facilitates a folded βII′-type turn conformation such that the
amino- and carboxyl-termini are closely apposed when bound to the receptor. Interestingly, in
jawless fish species (lamprey), and in the protochordates (sea squirt species) a chiral amino
acid is present in position 6 thus hindering the adoption of the folded conformation and
suggesting that, in these species, the peptides bind to the receptor in a more extended
conformation (see below). In vertebrates, the GnRH sequence is represented as a single copy
within a gene and the active peptide is cleaved from the precursor protein by processing
enzymes [90,100,127]. In contrast, several GnRH sequences are encoded in tandem within
single genes in protochordates [2].
3. Three-dimensional structure of GnRH I
The notion that in the jawed vertebrates glycine in position 6 allows folding of the GnRH to
bind its receptor was supported by the demonstration that protochordate GnRHs with the chiral
amino acid in position 6 had very poor activity at vertebrate GnRH receptors but this activity
could be enhanced more than 10-fold by substitution with the achiral glycine in position 6 (Fig.
4) [9]. In contrast, protochordate GnRH receptors from sea squirts (tunicates) did not
distinguish between the GnRHs with different amino acid residues in this position suggesting
that the peptide is able to interact with the receptor binding sites in a more extended form and
that evolution of receptors requiring interaction with GnRH in the folded conformation only
arose after the evolution of jawed vertebrates. Structural analysis of the GnRHs using a
combination of ion-mobility mass spectrometry and molecular modeling revealed a close
correlation between the propensity for the formation of the βII′-type turn conformation (e.g.
mammalian GnRH and a Gly6-substituted sea squirt GnRH) and higher binding affinity at
vertebrate receptors [9] (Fig. 5). These findings indicated that the substitution of glycine for a
chiral amino acid during evolution facilitates a more constrained conformation of GnRH for
receptor binding and that this subtle single amino acid substitution in a site remote from the
ligand functional domains has marked effects on its structure and activity.
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In the absence of a crystal structure of GnRH, indirect studies utilizing fluorescence
spectroscopy [97,130], region specific antisera [91], conformational memory approaches
[45] and NMR [17,77] support the above conclusion that mammalian GnRH I adopts the folded
structure. A three-dimensional structure of GnRH based on a recent NMR report (PDB code:
1YY1) is shown in Fig. 6. We have utilized this three-dimensional structure when interrogating
the binding of GnRH to its cognate receptor (see below).
4. GnRH receptor structure and function
The first cloning of the mammalian GnRH receptor was accomplished by Tsustmi et al.
[141] utilizing RNA from the LβT2 mouse gonadotrope cell line. Subsequently, a large number
of GnRH receptors have been cloned from many species in all the major vertebrate classes as
well as from modern representatives of protochordate progenitors of the vertebrates (see review
[95]). In addition, GnRH receptor orthologs have been cloned from a mollusc [122] and an
insect [50] and even from the primitive nematode, Caenorhabditis elegans [95]. However, it
is intriguing that the cognate ligand for these receptors is not GnRH and that GnRH evolved
later as a ligand for the receptor. In Drosophila, the cognate ligand is a nonapeptide called
adipokinetic hormone [134].
The GnRH receptors are classical G protein-coupled receptors (GPCRs) with seven
transmembrane domains (TMs) connected by extracellular loops (ECLs) and intracellular
loops (ICLs). They are members of the Class A or Group 1 rhodopsin family of GPCRs and
carry the hallmarks of conserved amino acid residues of the rhodopsin superfamily (see Fig.
7). The human and all mammalian pituitary GnRH receptors (designated type I GnRH
receptors) [95] are characterized by the unique absence amongst GPCRs of a carboxyl-terminal
tail. In all other GPCRs and the GnRH receptors from non-mammalian vertebrates and the
protochordates, there is a carboxyl-terminal tail which is the target for homologous and
heterologous phosphorylation which results in the docking of β-arrestin. This event results in
a rapid desensitization of the receptor through uncoupling to G proteins and also mediates
receptor internalization (see below).
A number of highly conserved amino acid residues are present in all members of the rhodopsin
family, particularly in the 7-TM domains, and almost all GPCRs can activate G-proteins,
supporting the concept that GPCRs share a common protein folding and activation mechanism.
However, the human and other mammalian GnRH receptors have some unusual features in
addition to the absence of a carboxyl-terminal tail such as a reciprocal exchange of the
conserved Asp2.50-Asn7.49 pair in TM 2 and TM 7 (Fig. 7). We demonstrated that mutation of
Asn87(2.50) to Asp abolished receptor function, but a second mutation of Asp318(7.49) to Asn
in the mouse GnRH receptor, recreating the arrangement found in other GPCRs, restored ligand
binding [146]. This restoration of ligand binding by reciprocal mutation demonstrates that the
side-chains of the two residues in TMs 2 and 7 have complementary roles in maintaining the
structure of the receptor and occupy the same microenvironment within the receptor helical
bundle. Subsequently, the crystal structure of bovine rhodopsin revealed that these residues
are capable of interacting through a water molecule [110] thus validating the GnRH receptor
models. Interestingly, this exchange prevents the human GnRH receptor coupling to
phospholipase D by the small G-proteins ARF and RhoA, implying receptor conformation-
dependent signaling selectivity [98].
We have built a homology model of the human GnRH receptor in the inactive state using the
high-resolution crystal structure of bovine rhodopsin in the dark state (1U19) as a template
with the “MODELLER” module within DS Modeling (version 1.6, Accelrys, San Diego, CA,
USA). The use of the rhodopsin crystal structure to comparatively model the GnRH receptor
has been extensively validated by our laboratory and independent groups using site-directed
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mutagenesis and peptide and non-peptide ligand docking [10,53,132]. All known GnRH
receptor sequences from a wide range of species were aligned with bovine rhodopsin using
“ALIGN2D” within the MODELLER program. This was followed by minor manual
adjustments ensuring that the most highly conserved residues, motifs, and the disulfide bridge
Cys114–Cys196 were located at the same place as in the rhodopsin structure. The experimentally
identified disulfide bond between Cys14, in the N-terminal domain and Cys200 in the second
extracellular loop (ECL 2) [27] was also incorporated into the model as an additional constraint
of the receptor structure. The MODELLER-generated models with the highest values of the
3D-profile score were selected for refinement according to the experimentally identified
receptor inter- and intra-molecular interactions. The model was then subjected to energy-
minimization and molecular dynamics (MD) simulations by means of the CHARMM program.
Harmonic constraints of 2.5 kcal/mol/Å2 on the receptor backbone atoms were applied to allow
small conformational changes without loss of the overall topology. The model reveals the
experimentally identified hydrogen bonds between Asn53(1.50)-Asn87(2.50)- Asp319(7.49),
between Asp98(2.61)-Lys121(3.32), and between Asp138(3.49)-Arg139(3.50) (Fig. 8). This model
has provided insights into the potential intramolecular contacts between the seven-TM domains
of the human GnRH receptor which are involved in receptor folding, tertiary structural
configuration and receptor activation. Using site-directed mutagenesis guided by molecular
modeling, we have identified a number of receptor intramolecular interactions (Fig. 8) which
modulate receptor conformational states accounting for ligand binding selectivity and signaling
efficacy. Mutations of certain residues in the intracellular segments of TM domains to Ala
(Met132(3.43), Met227(5.54), Phe272(6.40), Phe276(6.44) and Ile322(7.52)) of the human GnRH
receptor allosterically increased ligand binding affinity for GnRH II, but had little effect on
GnRH I binding affinity [75]. We propose that these residues form part of the receptor
intramolecular allosteric network (Fig. 8) which transfer to specific ligand structural elements.
Disruption of the intramolecular interactions by mutation of the network residues alters the
receptor conformational state, changing ligand binding and signaling selectivity. This aspect
is considered in greater depth later in the article.
The crystal structure of a photoactivated deprotonated intermediate of rhodopsin reveals that
transformation of rhodopsin from the ground state to the intermediate state involves only minor
changes in the structure, in contrast to earlier predictions of major structural rearrangements
[124]. This indicates that a relatively subtle change can generate different receptor
conformational states. We have built an active human GnRH receptor model based on this
crystal structure (PDB code: 2I37) using a similar method to that described above. A βII′-type
turn conformation of GnRH I (derived from an NMR structure; PDB code: 1YY1) and of GnRH
II were docked into the model according to the experimentally identified GnRH binding sites
(Fig. 9). GnRH ligand docking requires a large displacement of ECL 2 and the disulfide bonded
N-terminal domain. The ligand–receptor complex was then optimized by energy-minimization
and MD simulations of 150 ps using a similar setup as described for the oxytocin receptor
[35] with harmonic restraints (2.5 kcal/mol/Å2) on the receptor backbone atoms except for
ECL 2 and the N-terminal domain. The molecular docking shows the intermolecular
interactions between GnRH I and the receptor: pGlu1 interacts with Asn212, His2 with
Lys121/Asp98, Tyr5 with Tyr290, Arg8 with Asp302 and Pro9-Gly10NH2 with Trp101/Asn102
(Fig. 9). Interestingly, when GnRH II is docked into the receptor model using the same
intermolecular interactions (His2 with Lys121, Pro9-Gly10NH2 with Trp101 and Asn102, and
His5 with Tyr290), Tyr8 of GnRH II (unlike Arg8 of GnRH I) faces away from Asp302 and
towards ECL 2. We therefore propose that the different intramolecular interactions between
Arg8 of GnRH I and Asp302 of ECL 3, and Tyr8 of GnRH II with residues in ECL 2 play
important roles in stabilizing different receptor active conformations with differing signaling
capability (see later).
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5. Absence of rapid desensitization and ligand-induced internalization of
mammalian GnRH receptors
Although chronic administration of GnRH agonists gives rise to a diminution in secretion of
biologically active gonadotropins and consequent decline in gonadal activity and sex steroid
hormone production, this is a slow pharmacological process which takes days to weeks and is
distinctly different from the classical rapid desensitization (min) and internalization of
receptors which occurs with the majority of GPCRs. Indeed, it is evident, that the unique
absence of a cytoplasmic carboxyl-terminal tail conveys a resistance of the GnRH receptor to
rapid desensitization and ligand-induced internalization as there is no recruitment of β-arrestin
[26,82,95,143]. Consequently, the receptor experiences prolonged activation and the
elimination of the cytoplasmic carboxyl-terminal tail during evolution may have arisen in order
to allow increased duration of gonadotropin secretion required for oocyte stimulation and
ovulation. This lack of desensitization has consequences in the ability of chronic GnRH
exposure to inhibit proliferation and induce apoptosis in tumor cells expressing the GnRH
receptor. Inhibition of gonadotropin by GnRH agonist treatment is frequently attributed to
GnRH receptor “down-regulation” and loosely as “desensitization”. However, it is evident that
this is incorrect as gonadotropin α-subunit remains massively elevated even after years of
treatment with GnRH agonist in prostate cancer patients. Thus, GnRH receptors and
intracellular machinery are continuing to respond to GnRH agonist but biologically active
mature gonadotropins are no longer produced.
The internalization pathways utilized by GnRH receptors differ between receptor sub-types.
The lack of a carboxyl- terminal domain in the mammalian type I GnRH receptors probably
accounts for their β-arrestin-independency for internalization [143]. This region has been
extensively reported to mediate GPCR interactions with β-arrestin [36]. Murine GnRH
receptors undergo a slow rate of internalization in αT3-1 and LβT2 cells, and the internalization
of human type I GnRH receptor expressed in αT4 pituitary cells proceeds at a slow rate and is
β-arrestin- independent [51]. This contrasts with the Xenopus type I GnRH receptor, which
possesses a carboxyl-terminal tail and internalizes more rapidly in a β-arrestin-dependent
manner when expressed in αT4 cells [51]. It appears that mammalian and non-mammalian
GnRH receptors can both be targeted for clathrin-mediated internalization, regardless of their
β-arrestin-dependence or independence. The catfish and chicken GnRH receptors both exhibit
rapid internalization kinetics and were shown to be dependent on their carboxyl-terminal tail
domains for this process [12,13,112]. The chicken GnRH receptor internalized 125I-[His5,D-
Tyr6]GnRH at an initial rate of 11.3% of surface receptor per minute to a maximal level of
approximately 75%, compared with only 0.71% per minute and maximal level of 25% for the
human GnRH receptor in the same cellular background. To determine whether the presence
of the cytoplasmic carboxyl-terminal tail was responsible for the more rapid internalization of
the chicken GnRH receptor, the tail was truncated at Ser337. Internalization of 125I-[His5, D-
Tyr6]GnRH by the Ser337- stop-chicken GnRH receptor was much slower than the wild-type
chicken receptor, and displayed similar internalization kinetics to the human GnRH receptor,
with a rate of 0.55% per minute and a maximal level of approximately 25% [112]. A threonine-
doublet located at the distal end of the chicken GnRH receptor cytoplasmic tail was shown to
be critical, as was a membrane proximal cysteine residue [114]. The chicken GnRH receptor
was shown to preferentially undergo rapid agonist-induced internalization in a dynamin- and
caveolae-dependent (but arrestin-independent) manner, and palmitoylation of the membrane
proximal cysteine residue may serve to target the chicken GnRH receptor to caveolae
microdomains for signaling and internalization [114]. The internalization pathways of the three
bullfrog GnRH receptor subtypes have been partially characterized [1]. The bullfrog type I
GnRH receptor was shown to internalize via a β-arrestin and dynamin-dependent pathway,
whereas the bullfrog type II and III GnRH receptors internalize via a pathway that is β-arrestin-
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independent, but dynamin-dependent, similar to the pathway utilized by the chicken GnRH
receptor [1,114]. Unlike all the mammalian type I GnRH receptors, the cloned marmoset type
II GnRH receptor [94] has a carboxyl-terminal tail, and a study identified a serine-doublet in
the carboxyl-terminal tail as critical for internalization of the type II GnRH receptor and
suggested that these residues undergo phosphorylation by GRKs. However, neither of these
residues, nor the carboxyl-terminal tail, was shown to be required for β-arrestin-dependent
internalization [123]. The above studies thus suggest that the carboxyl-terminal tail of the non-
mammalian GnRH receptors and mammalian type II GnRH receptors plays a pivotal role in
their function and sub-cellular trafficking to divergent internalization pathways. While there
is clearly divergence in the internalization pathways utilized by the tailed GnRH receptors, the
sequence motifs and structural elements within the cytoplasmic carboxyl-terminal domain that
determine which internalization pathway will be utilized have yet to be properly elucidated.
By measuring the trafficking of radioactive GnRH agonists, the above studies concluded that
mammalian type I GnRH receptors undergo slow ligand-dependent internalization. However,
by the direct measurement of mammalian type I GnRH receptor trafficking both in the presence
and absence of unlabeled GnRH agonist we have measured low basal levels of constitutive
agonist-independent internalization [115]. Stimulation with GnRH agonist did not significantly
enhance the level of mammalian type I receptor internalization above the basal level, in contrast
to mammalian receptor chimeras with cytoplasmic tails, or the TRH receptor [115]. These data
suggest that as a result of the deletion of the cytoplasmic carboxyl-terminal tail during evolution
the mammalian type I GnRH receptors was directed at avoiding internalization and
desensitization for prolonged activation of the pituitary receptor [26,82,115]. Recent
biophysical evidence for type I GnRH receptor self-association and localization to low-density
membrane microdomains highlights the complexities of GnRH receptor multi-protein
scaffolding and trafficking processes [11,52,106,107]. Although agonists and antagonists both
slow type I GnRH receptor lateral diffusion, only agonists induce the formation of large multi-
protein complexes [52]. These events are apparently not related to receptor internalization
which is identical for antagonists and agonists [115]. The biophysical approaches used by Clay
and colleagues [11,52,106,107] may provide the means for investigating ligand-induced
selective signaling at the GnRH receptor in different cell types following the binding of
different GnRH analogs (see below) [89,95].
6. Most vertebrates have several GnRH forms and several cognate GnRH
receptors serving diverse functions
Elucidation of the sequence of GnRHs and GnRH receptors from a wide range of vertebrates
revealed that multiple forms of the ligands and multiple forms of cognate receptors exist in the
majority of vertebrates. Phylogenetic analysis of the gene sequences further revealed that there
are three families of ligands and receptors [95,100]. In teleost fish and amphibians it is apparent
that there are three GnRHs and three cognate receptors which have a wide tissue distribution
indicating that they have been co-opted as regulators of diverse functions. In the central nervous
system of teleost fish, the three GnRHs are discretely distributed. GnRH I is localized in the
preoptic area and appears to be a major regulator of pituitary function. GnRH II is localized in
the mid-brain and is thought to be a regulator of reproductive behavior, GnRH III is localized
in the terminal nerve area of the forebrain and appears to regulate olfactory systems. Indeed,
there is apparently a coordinated activation of these three GnRH systems in some species such
as the salmon to regulate several aspects of reproduction. When salmon begin their migration
from the ocean up rivers to their spawning grounds, it appears that the GnRH I neurons become
activated to stimulate pituitary gonadotropins, GnRH II neurons become activated to stimulate
reproductive behavior and GnRH III neurons are activated to sensitize the olfactory system to
allow detection of chemicals for navigation to spawning streams (Swanson et al., personal
communication).
Millar et al. Page 7
Front Neuroendocrinol. Author manuscript; available in PMC 2009 April 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
GnRH I is highly variable in structure amongst vertebrates while the GnRH II structure is
totally conserved in jawed vertebrates. The GnRH III structure is also conserved in teleosts.
GnRHs are known to regulate pituitary hormones other than gonadotropins in teleost fish and
it is intriguing that distinct GnRH receptor subtypes are discretely localized to gonadotropes,
somatotropes and lactotropes [111]. An example of the co-localization of the teleost type IA
and type III receptors with gonadotropes and somatotropes, respectively, is shown in Fig. 10.
GnRH and the receptors are also expressed in the gonads of teleost fish where they affect
gametogenesis and steroidogenesis. In addition to actions in the central nervous system,
pituitary and reproductive tissues, it is apparent that GnRHs and their receptors have also been
recruited during evolution to regulate the peripheral nervous system. In the bullfrog, the type
II GnRH receptor is expressed in the sympathetic ganglion and GnRH II is a potent regulator
of M currents (inward rectifying K+ channels) which causes a partial depolarization and
sensitization of neurons [14,55,57,140].
In reptile, bird and mammalian species only two GnRHs (GnRH I and GnRH II) and two
receptors ( type I and type II) are present. This suggests that the third form of GnRH and the
third receptor were eliminated from the genome during the transition from amphibia to reptiles.
An alternative, but probably less cogent possibility is that there was an additional gene
duplication of GnRH and the GnRH receptor in teleosts and amphibia subsequent to the
evolution of the reptiles, to give rise to the third ligand and receptor.
7. Potential functions of GnRH in mammals
Hypotheses suggesting multiple physiological roles for GnRH in mammals have been
proposed, sometimes by extrapolation, from the comparative tissue distribution of GnRH
peptides or their receptors in fish, amphibian, avian and mammalian species [71,78,118,121,
133,144]. However, the extent to which the biological roles of GnRH in mammals, compared
to other vertebrates, have been modified, superseded or abandoned during evolution is not yet
fully understood. Nevertheless, theories concerning the function of GnRH in neuronal,
neuroendocrine and reproductive tissues during mammalian development have been
considered [56,72,120]. The functions for GnRH in juvenile to adult reproductive maturation
and in the maintenance of adult reproductive tissues via autocrine-paracrine mechanisms are
both common themes [15,41,68]. The manner in which local GnRH action modulates the
physiology and patho-physiology of reproductive tissues is a focus of investigation [23,48,
139]. More specialized roles in blastocyst implantation, physiological changes occurring
during pregnancy, including modulation of the cellular immune system, and influences on
reproductive and parental behavior are also regarded as possibilities in certain mammalian
species [15,19,22,40,59,61]. Many mechanistic questions concerning the precise involvement
of GnRH in such diverse processes remain unanswered. For example, we do not fully
understand the roles of GnRH in the mammalian central nervous system. Some detailed
mapping and functional analyses of GnRH I and GnRH II neurons have been performed in
mammals [28,29,131,145]. However, the action of GnRH on GnRH neurons or their
neighboring cells has not been characterized in great depth, although several model cell lines,
derived from mouse hypothalamic GnRH neurons, have provided the foundations for further
functional studies [84,119]. More recently, the role of the metastin/kisspeptin receptor (gpr54)
in influencing GnRH neuron function has been elucidated [30,85,117,138], but how
mammalian GnRH I and GnRH II and the type I or type II GnRH receptors integrate into the
complexity of neuronal function, in both males and females, still requires further elaboration.
8. Silencing of GnRHs and GnRH receptors in mammals
GnRH I and GnRH II and the two types of GnRH receptor (type I and type II) are present in
the majority of mammalian species studied. Comparative genomics shows that the genes
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encoding mammalian GnRH ligand precursors and receptors exhibit a remarkable degree of
syntenic conservation, exhibited by the retention of particular and characteristic flanking genes
at the relevant chromosomal loci [100]. Furthermore, analysis of DNA sequence data and
functional studies indicate that there has been sporadic silencing or deletion of GnRH II and/
or the type II receptor in various mammals. Thus, GnRH I and GnRH II and the type I and type
II GnRH receptors are expressed in some primates such as the marmoset [94] and green monkey
while the type II GnRH receptor has been silenced in man and the chimpanzee by stop codons
and frame shifts [101]. From a molecular genetics point of view, it is possible that, during
evolution, the mammalian type II GnRH receptor gene came under functional pressure by close
apposition of 5′ and 3′ anking genes (potentially leading to interference with transcription) and
subsequent mutations led to gene silencing. The GnRH II peptide precursor also appears to
have been inactivated in the chimpanzee by a premature stop codon. In contrast, both forms of
GnRH and receptors may be functional in the pig while both GnRH II and the type II receptor
have been silenced through stop codons, deletions and substitutions in the sheep and cow
[102]. The 3.7 kb genomic DNA segment lying between the conserved pex11b and RBM8
genes on mouse chromosome 3 does not contain a type II GnRH receptor gene (see Ensembl
database, www.ensembl.org) and a similar situation is apparent for the 5.2-kb pex11b–RBM8
inter-genic region on rat chromosome 2. Bioinformatics analyses suggest that the type II GnRH
receptor gene and the GnRH-II precursor gene have been deleted from the genomes of
laboratory mouse and rat strains. This is not the case for all small mammalian species. For
instance, a gene encoding a type II GnRH receptor is retained in the genome of insectivores,
such as the common shrew (Sorex araneus) and the musk shrew (Suncus murinus) (Ensembl
database and K. Morgan, unpublished data), known to express a functional GnRHII peptide
hormone. These observations coupled with other data suggest that the GnRH I/type I receptor
system could substitute for the GnRH II/type II receptor system in some species. Interestingly,
GnRH I and the type I GnRH receptor are never silenced, only the type II system. This is
understandable as the type I GnRH receptor binds GnRH I and GnRH II well, while the type
II GnRH receptor is highly selective for GnRH II and binds GnRH I with very low affinity
[86]. Thus the type I GnRH receptor can substitute as a mediator of GnRH II actions but the
type II GnRH receptor cannot mediate GnRH I actions.
9. GnRH II as a regulator of reproductive behavior
GnRH I and GnRH analogs as well as fragments of GnRH I were shown to stimulate lordosis
in female rats many years ago [103]. Subsequently, GnRH II was shown to stimulate courting
behavior in ring doves [20] and induces female solicitation of males in song sparrows [78].
GnRH also stimulates spawning behavior in the gold-fish [142]. Another study demonstrated
stimulation of male behavior by injecting GnRH II into female green iguanas [116]. In the
green anole [3] GnRH also stimulates reproductive behavior. These findings encouraged
further exploration of GnRH actions on reproductive behavior in other mammalian species.
Introcerebroventricular administration of GnRH II was shown to stimulate sexual behavior in
female musk shrews, while GnRH I was inactive (Fig. 11) [137]. Moreover, an antagonist at
the type I GnRH receptor which is an agonist at the type II GnRH receptor (antagonist 135-18
stimulates reproductive behavior in female musk shrews suggesting that the effect is mediated
by the type II receptor [60]. This conclusion is further supported by the demonstration that
antide which is an antagonist at the type I receptor but is inactive at type II receptors, had no
effect on GnRH II stimulation of behavior. Interestingly, these effects could only be
demonstrated after food restriction and GnRH II itself was found to inhibit feeding behavior
in musk shrews [59,60]. Thus, it appears that under normal conditions when animals are satiated
the endogenous GnRH II system is fully activating reproductive behavior and exogenous
GnRH II is not required. In food restrained animals GnRH II in the midbrain appears to be
decreased such that exogenous GnRH II administration can re-instate reproductive behavior.
These researchers also showed that GnRH II decreased short-term feed intake. There appears,
Millar et al. Page 9
Front Neuroendocrinol. Author manuscript; available in PMC 2009 April 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
therefore, to be an interesting dual effect of GnRH II in that at the time that it stimulates
reproductive behavior it also inhibits feeding. Thus, GnRH II can play a pivotal role in
integrating nutritional status and reproduction which is crucial for survival. This participation
of the GnRH system in the relationship between nutrition and reproduction appears to have
ancient evolutionary origins as we have found that a GnRH receptor ortholog is expressed in
the neuroscrecretory motor neurone in C. elegans which integrates feeding and reproduction
(Swanson et al., unpublished).
These studies suggested that GnRH II may also be effective in primates. Studies on the effect
of GnRH II on proceptive female behavior in ovariectomised and estrogen replaced female
marmosets [8] indicated that intracerebral infusion of GnRH II at 1 and 10 μg doses stimulated
proceptive behaviors in the absence of estrogen replacement (Fig. 12). In the presence of
estrogen replacement, the peptide was found to be less effective. Thus, similar to the effect of
feeding in the musk shrew estrogen may be activating the GnRH II system and exogenous
GnRH II is less effective. A model encapsulating these proposals is outlined in Fig. 13. As in
the musk shrew experiment, we also utilized a GnRH antagonist which inhibits the type I GnRH
receptor but acts as an agonist at the type II GnRH marmoset receptor. The antagonist 135-18
at 1 μg icv was able to Significantly stimulate proceptive behavior in the female marmoset in
the absence of estrogen but was ineffective in the presence of estrogen. Another antagonist
135-25 which has similar agonistic properties to 135-18 at the type II GnRH receptor [8] was
also able to stimulate proceptive behaviors in the female marmosets at a dose of 1 μg in the
absence of estrogen replacement. In contrast, GnRH I at a dose of 1 μg was ineffective at
stimulating proceptive reproductive behaviors. Thus, the pharmacology of GnRH analog
effects on reproductive behavior is distinctly different from effects on stimulating
gonadotropin. For the marmoset this difference is due to the involvement of two distinct
receptors (type I and type II) which have been cloned and shown to exhibit different
pharmacology. The musk shrew appears to be utilizing a similar system as both receptors
appear to be present (Morgan et al., in preparation). In contrast, the aberrant pharmacology for
GnRH analog effects on behavior in the rat described many years ago [103] cannot be the result
of utilizing a type II GnRH receptor as it has been deleted from the rat genome [100]. It therefore
appears that a different pharmacology can be manifested at the type I receptor due to the
intracellular context (see LiSS below).
10. Direct inhibition of proliferation and stimulation of apoptosis in cancer
cells by GnRH analogs
GnRH agonists are extensively used in the treatment of sex hormone-dependent cancers.
Chronic administration of these agonists induces the desensitization of pituitary gonadotropes
resulting in a decrease in sex steroid hormone secretion and amelioration of the disease.
However, a plethora of studies also points to direct inhibitory effect of GnRH analogs in cancer
cells.
Responses of post-menopausal women with breast cancer to GnRH analogs [49] suggested
that GnRH analogs may also have direct antiproliferative effects which are independent of their
actions in decreasing sex steroid hormones. The presence of GnRH receptors in breast cancer
tissue [31] and the demonstration of antiproliferative actions of GnRH analogs in breast cancer
cell lines [32,47,96] supported this interpretation. Antiproliferative effects of GnRH analogs
and the expression of GnRH receptors have now been demonstrated in a number of cell lines
of reproductive tract tumors, including prostate, uterine and ovarian cancers, and also in non-
reproductive tract tumors [21,43,47,70,73,79]. In contrast to GnRH actions at the gonadotrope,
which are mediated through the Gαq protein, these antiproliferative and apoptotic effects on
tumor cells are thought to be mediated via the Gαi protein [42,54,81], focal adhesion complexes
involving c-Src, and the JNK and P38 stress-activated kinases [42,54,70,73,81]. Other
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mechanisms which have been implicated in the antiproliferative effects, include the down-
regulation of growth factor actions by decreased expression of growth factors and their
receptors and activation of phosphotyrosine phosphatase [42], and the inhibition of Akt and
the 60S acidic ribosomal phosphoproteins which modulate cell survival and protein synthesis
[18,62,63,69,74,136]. We have demonstrated that the effects of a series of GnRH analogs on
antiproliferation and apoptosis in cancer cell lines is very different from their effects on
gonadotropin secretion [81]. We have dubbed the phenomenon “ligand-induced selective-
signaling” (LiSS) [81,89,95] (Fig. 14). Thus GnRH II [88,113] is more potent than GnRH I in
the inhibition of cell growth while GnRH II is less potent than GnRH I in stimulating the
Gαq pathway for gonadotrophin secretion. An extreme difference is the pure antagonism of
antagonist 135-25 at Gαq while it acts as a full agonist in inhibiting cell growth (Fig. 15). A
number of antagonists of gonadotrope GnRH receptors act as GnRH agonists in the inhibition
of tumor cell lines [32,34,44,81,128].
Research on the structure–activity relationship (SAR) of GnRH analogs has focused on the
ability of ligands to modulate Gαq activation which stimulates gonadotropin secretion. Since
antiproliferative and apoptotic effects are mediated by different signaling pathways from those
stimulating gonadotropins, we have undertaken a SAR study on the inhibition of cell number
by GnRH analogs using a model system of HEK 293 cells expressing either the rat or the human
GnRH receptor. Since GnRH II is more potent than GnRH I, the three different amino acids
in GnRH II (His5, Trp7 and Tyr8) were systematically incorporated into synthetic GnRH I
peptides and the relative antiproliferative and inositol phosphate production (Gαq) compared.
Tyr5 substitution by His5resulted in increased affinity, which correlated with higher potencies
for both of the responses studied. Trp7 substitution for Leu7 into GnRH I did not Significantly
modify binding affinity and inositol phosphate (IP) production (Gαq) but increased potency
10- to 20-fold for the inhibition of cell growth. The substitution of Arg8 in GnRH I by Tyr8
was the single change that resulted in the most selective inhibitor of cell growth. At the rat
receptor, [Tyr8]GnRH I was >30-fold less potent in IP generation but 4-fold more potent in
inhibiting cell growth, compared to GnRH I. Although this analog has a very low potency for
IP production, it is still more potent than GnRH I in inhibiting cell growth and is thus the most
selective analog for inhibiting cell growth. Analogs with double substitutions [His5,Trp7]
GnRH I and [His5,Tyr8]GnRH I, displayed properties approximating the product of the single
substitutions.
In Fig. 16 the ratio of IP and inhibition of cell growth shows that analogs with Tyr8 are generally
the most selective for cell growth inhibition. We have examined the possible explanation for
the enhanced selective inhibition of cell growth with the substitution of Arg8 by Tyr8 in GnRH
I. It appears that the substitution of Arg8 with Tyr8 enables the ligand and receptor to adopt
new conformations that better stabilize the receptor in the active state that mediates the
antiproliferative/apoptotic effect. Our studies on the docking of GnRH I and GnRH II with the
refined rhodopsin homology model of GnRH receptor [75] reveal that Arg8 satisfactorily
interacts with Asp302, but when GnRH II is docked to the receptor, Tyr8 faces away from
Asp302 and appears to make contacts with residues in ECL 2 thus stabilizing a different receptor
conformation (see earlier section on GnRH receptor and Fig. 9 therein). Hence, the findings
that substitution of Arg8 with Tyr8 give rise to a decrease in IP generation but increase in the
inhibition of cell growth suggests that Arg8 of GnRH I stabilizes a receptor conformation with
preferential Gαq coupling, while its substitution with Tyr favors a receptor conformation
associated with signaling to proapoptotic and antiproliferative pathways. These findings further
support the LiSS concept. This is exemplified by the natural GnRH I and GnRH II ligands,
which show inverted potency ratios for the stimulation of inositol phosphate synthesis and
inhibition of cell growth and this has been further refined in the [Tyr8]GnRH I analog. These
studies together with those on GnRH antagonists reveal four distinct classes of analogs (Table
1) with the potential for more selective actions as therapeutics.
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11. Differential GnRH receptor conformations dictate different ligand-
selectivity and different signaling
Since GnRH II was more potent than GnRH I in the inhibition of cancer cells but less potent
in stimulating inositol phosphate production, which mediates gonadotropin secretion in the
pituitary, we proposed that the two ligands are able to preferentially stabilize different
conformations of the type I GnRH receptor which give rise to differential signaling output (Fig.
14). This LiSS concept predicts that GnRH I and GnRH II make common and different contacts
with the type I GnRH receptor which stabilize different receptor conformations and which
transduce different intracellular signaling. Molecular support for this concept requires a
detailed delineation of the binding sites for GnRH I and GnRH II as well as the identification
of the intramolecular receptor interactions which stabilize the receptor in different
conformations which are differentially selective for ligands and intracellular signaling. These
elements were described in the section on GnRH receptor structure and function. GnRH I and
GnRH II were found to utilize common receptor interacting sites for positions 1, 2, 3, 5, 9 and
10 but employ different sites for interactions with the amino acids in position 8 (Arg and Tyr)
(Fig. 9).
Intramolecular interactions in the TMs which control receptor conformational states and
consequent ligand binding selectivity and signaling efficacy were identified as (Met132(3.43),
Met227(5.54), Phe272(6.40), Phe276(6.44) and Ile322(7.52)) (Fig. 8). Mutation of these residues
increased ligand binding affinity for GnRH II, but had little effect on GnRH I binding affinity
[75] (Fig. 17). We then examined the role of the three amino acids which differ in the two
endogenous ligands and found that Tyr8 in GnRH II plays a dominant role for the increased
affinity of the receptor mutants for GnRH II. We propose that creation of a high affinity binding
site for GnRH II accompanies receptor conformational changes, i.e. “induced fit” or
“conformational selection”, mainly determined by the intermolecular interactions between
Tyr8 and the receptor contact residues, which can be facilitated by disruption of particular sets
of receptor-stabilizing intramolecular interactions. On the other hand, Arg8 of GnRH I
interacted with Asp302 of the receptor to stabilize a different conformation. Thus these
mutations result in a change in ligand selectivity which closely parallels our observations on
the inhibition of cell growth. We therefore predict that these mutant receptors will be more
effective in inhibiting cell growth as they stabilize the receptor conformations which are
selective for GnRH II and [Tyr8]GnRH.
The findings suggest that the human type I GnRH receptor is evolutionarily configured for
high affinity binding of GnRH I, but has a lower affinity for GnRH II and GnRHs from other
species which differ from GnRH I at position 8. These natural GnRHs in which Arg8 is
substituted by a neutral amino acid are partial agonists in the activation of inositol phosphate
generation but potent antiproliferative agents (our unpublished data). Mutation of
Cys279(6.47) to Ala or Tyr (a mutation causing infertility in man) and Asn315(7.45) to Ala
increases ligand binding affinity for GnRHs from other species and converts them to full
agonists [76]. Recent studies have shown that partial agonists stabilize a receptor active
conformation differing from that of full agonists, with different signaling capability [6,109].
Taken together these findings suggest that a complex receptor intramolecular interaction
network evolved during evolution for selective binding of ligands and G protein activation.
These highly conserved amino acids apparently form part of an allosteric network which
constrains the receptor in inactive states. Substitutions of residues within this allosteric network
can result in subtle receptor conformational changes which alter receptor binding selectivity
for ligands and G proteins and might constitute one of the mechanisms for the evolution of
ligand binding and signaling selectivity and diversity of GPCR function. GnRH ligand-
induction of new receptor intra- and intermolecular interactions appears to be a fundamental
component for GnRH receptor activation. The delineation of the structural elements for ligand
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and receptor conformational selection could have implications for the development of novel
ligands that selectively activate certain signaling pathways, with improved therapeutic
application [76].
12. Conclusion and future perspectives
Geoffrey Harris’ discovery of the hypothalamic-hypophyseal portal system and the subsequent
identification of the humoral factors regulating pituitary hormone secretion have stimulated
the development of new diagnostic tools and therapeutic interventions. GnRH analogs, in
particular, have found extensive application in reproductive tract pathologies, in assisted
conception technologies and potentially in new contraceptive systems with reduced side-
effects. The discovery that GnRHs also regulate sexual behavior and have direct effects on
normal and neoplastic reproductive tissues holds the promise of novel therapeutic applications.
The discovery that GnRH analogs can be developed to specifically recruit certain signaling
pathways while by-passing others offers the opportunity of improving selectivity for
conventional and novel applications, with reduced deleterious effects.
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Fig. 1.
Geoffrey Wingfield Harris.
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Fig. 2.
Harris’ original demonstration of the capillary network (injected with India ink) connecting
the median eminence (P.T., P.V) with the pars distalis (P.D.) of the pituitary.
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Fig. 3.
Primary amino acid sequences of naturally occurring decapeptide gonadotropin-releasing
hormone (GnRH) structural variants spanning approximately 600 million years of evolution.
The boxed regions show the conserved amino- and carboxyl-terminal residues which are
involved in receptor binding and activation. The GnRHs are named according to the species
in which they were first discovered and they may be represented in more than one species. For
example, mammalian GnRH is widely conserved in amphibians and primitive bony fish, and
chicken GnRH II is present in most vertebrate species, including man. An octopus GnRH and
an additional Ciona GnRH comprising 12 and 16 amino acids, respectively, but retaining the
conserved amino- and carboxyl-terminal domains are not shown (Reproduced from [9]).
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Fig. 4.
Competitive binding of mammalian, Ciona and position six substituted Ciona I GnRHs to
human, Ciona A and chicken GnRH receptors transiently transfected in COS-7 cells. (a,b) ■,
mammalian GnRH; ▲, Ciona I GnRH; △, Ciona II GnRH; ○, Ciona III GnRH. (c,d) ■,
mammalian GnRH; ▲, Ciona I GnRH; ●, [Gly6]Ciona I GnRH; □, [D-Ala6]Ciona I GnRH
(Reproduced from [9]).
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Fig. 5.
Ribbon representations of peptide structures. The peptide backbone of: (a) Ciona I GnRH, (b)
[Gly6]Ciona I GnRH, and (c) mammalian GnRH are shown. The Ciona I peptides contain
protonated His2 and mammalian GnRH has Arg8 and His2 both protonated. Each is a snapshot
from dynamics performed with the Born–Solvent model, with the amino- and carboxyl-
terminal residues represented by CPK structure. The distance between the alpha carbons of the
terminal residues in each snapshot is marked. The [D-Ala6]Ciona I GnRH structure was similar
to [Gly6]Ciona I GnRH (not shown) (Reproduced from [9]).
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Fig. 6.
The NMR structure of GnRH I (PDB Code: 1YY1).
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Fig. 7.
Two-dimensional representation of the human GnRH receptor. The 7-TM domains (boxed)
are connected by 3 ECLs and 3 ICLs. Ligand binding residues (red) and residues thought to
be important in receptor structure or binding pocket configuration (green) are shown. These
include disulfide bond formation and glycosylation sites. Residues involved in receptor
activation are shown in blue. Residues in squares are ones highly conserved throughout the
rhodopsin-like family of GPCRs and designated as N.50 using the nomenclature of Ballesteros
and Weinstein. Residues involved in coupling to Gproteins are shown in orange. Putative
protein kinase C (PKC) and protein kinase A (PKA) phosphorylation sites are indicated. The
intermolecular interactions between GnRH I residues and the receptor are indicated with red
lines (Modified from [95]).
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Fig. 8.
A model of the 7-TM domains of the human GnRH receptor. The model shows the
experimentally identified receptor intramolecular H-bond interactions: Asn53-Asn87-Asp319;
Asp98-Lys121, Asp138-Arg139, and the hydrophobic interactions: Met132-Phe272-Ile322 (and
the surrounding residues Met227 and Phe276).
Millar et al. Page 29
Front Neuroendocrinol. Author manuscript; available in PMC 2009 April 8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 9.
Molecular docking of GnRH I and GnRH II. A βII′ conformation of GnRH I derived from the
NMR structure (1YY1) and GnRH II were docked into the receptor model according to the
experimentally identified and putative intermolecular interactions between GnRH and the
receptor. (a) GnRH I docking shows that pGlu1 interacts with Asn212, His2 with Lys121/
Asp98, Tyr5 with Tyr290 and Arg8 with Asp302 and Pro9Gly10NH2 with Trp101/Asn102. (b)
GnRH II docking shows the same contacts with the exception that the side-chain of Tyr8 of
GnRH II does not interact with Asp302 and instead faces away from Asp302 towards ECL 2.
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Fig. 10.
Coronal sections of adult fish pituitary immunofluorescence (A) gonadotropin-releasing
hormone receptor (GnRH-R) type IA labeled with Texas Red, (B) luteinizing hormone (LH)
β-subunit labeled with fluorescein-isothiocyanate (FITC) and (C) colocalization of GnRH-R
type IA and LH β-subunit is seen as yellow fluorescence using a dual-band filter. Sagittal
sections of adult pituitary immunofluorescence, (D) GnRH-R type III labeled with Texas Red
Texas Red, (E) growth hormone (GH)-containing cells labeled with FITC and (F)
colocalization of GnRH-R type III and GH cells seen as yellow fluorescence using a dual-band
filter. Scale bar: (A–C) 200 μm; (D–F) 200 μm (Reproduced from [111]).
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Fig. 11.
Effects of icv administered GnRH I and GnRH II on latency to tail wag and frequency of mount
reception in female musk shrews. *Significant difference (p < 0.05) from other treatments
(Modified from [137]).
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Fig. 12.
Effect of icv administration of GnRH I, GnRH II and GnRH antagonist 135-18 on proceptive
behaviors in female marmosets. GnRH II and antagonist 135-18 were Significantly different
from vehicle control (Data derived from [8]).
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Fig. 13.
A proposed model of the role of GnRH II neurons in mediating reproductive behaviors in
female mammals.
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Fig. 14.
Schematic of the concept of multiple active states (conformers) of a single GnRH receptor
(R1–R4) that are selective for different agonist analogs (L1–L4). The different active receptor
conformers are selectively coupled to different signaling complexes (SC1–SC4) that give rise
to different effects in cells. Similar to Kenakin’s “agonist trafficking of receptor signals” we
envisage that a specific agonist (e.g. L1) will selectively bind and stabilize the active receptor
conformer (R1), which will activate signaling complex (SC1). In the presence of L1 and the
absence of other agonists, more of R1 will be stabilized and more SC1 is recruited and activated
(shown in bold black). It also follows that the presence of more protein complexes comprising
SC1 (e.g. a specific cell type, or prior homologous or heterologous receptor activation resulting
in phosphorylation etc.) will stabilize more of active receptor conformer R1and increased
binding of R1-selective agonist L1 (Modified from [89]).
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Fig. 15.
Effects of GnRH I, GnRH II and GnRH antagonist on stimulation of Gαq (inositol phosphate
production) (blue) and inhibition of proliferation (red) in a novel cell line of HEK 293 cells
stably transfected with the rat GnRH receptor. Similar pharmacology is observed in human
cancer cells expressing the GnRH receptor.
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Fig. 16.
Relative effects of GnRH I analogs substituted with GnRH II residues (His5, Trp7 and Tyr8)
on inositol phosphate production (IP) and antiproliferative activity (PA) in HEK 293 cells
stably expressing the rat GnRH receptor. Note that Tyr8 substitution produces analogs with
greater antiproliferative selectivity. Data represent the mean ratios derived from three or more
experiments. The analogs with Tyr8 had Significantly higher ratios than GnRH I.
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Fig. 17.
Competition binding of GnRH I and GnRH II in human wild-type and Ala mutant receptors
of Met132 and Phe272. (a) GnRH I binding; (b) GnRH II binding. ●, wild type; ▼, M132A;■,
F272A (Reproduced from [75]). Note the large increase in affinity for GnRH II but not GnRH
I when residue M132 or F272 remote from the binding site is mutated to Ala suggesting the
generation of a different receptor conformation with different ligand selectivity.
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Table 1
Classes of GnRH modulators for cancer therapy
Classical agonist Novel agonist Classical antagonist Novel antagonist
Steroid inhibition (Gq) Yes Slight Yes Yes
Direct inhibition (Gi) Yes Yes Slight Yes
Castration Yes No Yes Yes
Flare Yes No No No
Delayed onset Yes No No No
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